Base de dados : LILACS
Pesquisa : E02.186.079.500 [Categoria DeCS]
Referências encontradas : 18 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2 ir para página        

  1 / 18 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1056647
Autor: Alshewered, Ahmed Salih; Al-Naqqash, Manwar abdulelah.
Título: Rectal cancer and chemoradiation in Iraq: systematic review and meta-analysis / Câncer retal e quimiorradioterapia no Iraque: revisão sistemática e metanálise
Fonte: J. coloproctol. (Rio J., Impr.);39(4):309-318, Oct.-Dec. 2019. tab, ilus.
Idioma: en.
Resumo: Abstract Background: Rectal cancer is one of the most common malignant tumors of gastrointestinal tract. Combining chemotherapy with radiotherapy has a sound effect on its management. Objectives: Assessment the patterns of characterizations of rectal cancer. Evaluation of the efficacy, and long-term survival of pre-/ postoperative chemoradiation. Collecting all eligible evidence articles and summarize the results. Methods: By this systematic review and meta-analysis study, we include data of chemoradiation of rectal cancer articles from 2015 until 2019. The research was carried out at Baghdad Medical City oncology centers. Accordance with the PRISMA guidelines, and the Newcastle-Ottawa Scale used. Results: Starting with gender distribution as M:F ratio of 0.94:1.06. Regarding the age, recorded mean ± SD of 48.7 ± 14.2 years. Rectosigmoid represented the most common site as 50(49.5%), and adenocarcinoma was common histopathology as 76(75.2%) of patients, with localized stage in 50(49.5%). The moderate differentiation was most grade as 65(64.4%). The distant from anal verge mostly seen was 5-10 cm in 59(58.4%). The pulmonary was commonest site of metastasis in 11(10.9%). Most patients undergo APR operation, which has done in 41(40.6%). Adjuvant chemoradiation received by 40(39.6%) patients, whereas neoadjuvant chemoradiation gave to 25 patients. A total of 2609 articles from 12 databases met our search strategies. The highest Newcastle-Ottawa score (8) demonstrated in three studies, and median score (7) calculated in five studies. Conclusions: The incidence belonged to 5th and 6th decade of life. Rectosigmoid represented the most common site. Mostly, the 5-10 cm distant of tumor from anal verge was common finding. The pulmonary was most site of metastasis. We concluded the formulation of a novel point that survival benefit found in many pre or postoperative chemoradiation trials in rectal cancer.

Resumo Introdução: O câncer retal é um dos tumores malignos mais comuns do trato gastrointestinal. A combinação de quimioterapia e radioterapia em seu tratamento é eficaz. Objetivos: Avaliar os padrões de caracterização do câncer retal. Avaliar a eficácia e sobrevida a longo prazo em pacientes submetidos a quimiorradioterapia pré- ou pós-operatória. Coletar todos os artigos de evidências qualificados e resumir os resultados. Métodos: Esta revisão sistemática e metanálise incluiu dados de ensaios clínicos randomizados por cluster de 2015 até 2019. A pesquisa foi realizada nos centros de oncologia do Baghdad Medical City. As diretrizes PRISMA e a escala de Newcastle-Ottawa foram utilizadas para avaliar os estudos. Resultados: Quanto à distribuição por sexo, observou-se uma relação homem:mulher de 0,94:1,06. Em relação à idade, a média ± DP foi de 48,7 ± 14,2 anos. O retossigmoide fpo o local mais comum em 50 pacientes (49,5%); a histopatologia mais comum foi adenocarcinoma, observada em 76 pacientes (75,2%), com estágio localizado em 50 (49,5%). Diferenciação moderada foi observada em 65 pacientes (64,4%). A distância da borda anal variou entre 5 e 10 cm em 59 pacientes (58,4%). O pulmão foi o local mais comum de metástase, sendo observado em 11 pacientes (10,9%). A maioria dos pacientes (41 [40,6%]) foi submetida à ressecção abdominoperineal. Um total de 40 pacientes (39,6%) foram submetidos a quimiorradioterapia adjuvante e 25, a quimiorradioterapia neoadjuvante. Na revisão da literatura, foram encontrados 2.609 artigos que atendiam aos critérios de pesquisa utilizados em 12 bancos de dados. Três estudos atingiram o escore máximo na escala de Newcastle-Ottawa (8); cinco estudos atingiram o escore mediano (7). Conclusões: No presente estudo, a maior incidência de câncer retal foi observada entre a quinta e sexta décadas de vida. O retossigmoide foi o sítio tumoral mais comum. A maioria dos tumores estava localizado entre 5 a 10 cm de distância da margem anal. O pulmão foi o local mais importante de metástase. No presente estudo, quimiorradioterapia pré- ou pós-operatória estava relacionada a uma maior sobrevida em casos de câncer retal.
Descritores: Neoplasias Retais
Neoplasias Retais/tratamento farmacológico
Quimiorradioterapia Adjuvante
-Radioterapia
Tratamento Farmacológico
Quimiorradioterapia
Limites: Humanos
Masculino
Feminino
Tipo de Publ: Metanálise
Revisão Sistemática
Responsável: BR545.3 - Biblioteca ICBS


  2 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Id: biblio-1093256
Autor: Sánchez Acuña, Juan Guillermo; Morales Navarro, Denia; Hernández Feria, Orlando.
Título: Colgajo temporal en la reconstrucción de un defecto maxilar por exéresis de carcinoma ameloblástico / Temporalis muscle flap in the reconstruction of a maxillary defect caused by exeresis of ameloblastic carcinoma
Fonte: Rev. cuba. estomatol;56(4):e2108, oct.-dez. 2019. graf.
Idioma: es.
Resumo: RESUMEN Introducción: El carcinoma ameloblástico es una entidad rara que surge como una neoplasia primaria o a partir de un ameloblastoma preexistente. El colgajo de músculo temporal es una opción terapéutica frecuentemente empleada para la reconstrucción del defecto resultante luego de la exéresis quirúrgica. Objetivo: Presentar un caso clínico de restauración estética y funcional mediante reconstrucción con colgajo temporal de un defecto maxilar por exéresis de carcinoma ameloblástico, dada la infrecuente presentación de esta entidad. Caso clínico: Mujer de 49 años de edad, que refiere "una bola" en el paladar de 9 meses de evolución. Al examen físico facial presenta aumento de volumen en región infraorbitaria izquierda. Se realizó una tomografía axial computarizada en la que se constató la presencia de imagen hiperdensa en seno maxilar izquierdo con calcificación en su interior, produciendo lisis del hueso nasal y hueso cigomático infiltrando partes blandas. Se tomó muestra para biopsia que informó tumor de alto grado de malignidad correspondiente a carcinoma ameloblástico. En estudio radiográfico de tórax no se apreció presencia de metástasis pulmonar. Se realizó maxilarectomía de infra y mesoestructura, resección de la lesión con margen oncológico de seguridad y se reconstruyó el defecto palatino con colgajo pediculado del músculo temporal. Se indicó quimio y radioterapia como terapia adyuvante al tratamiento quirúrgico. Se mantuvo el chequeo posoperatorio mostrándose buena evolución clínica y una epitelización secundaria del músculo temporal en el área palatina con restauración de las funciones. Conclusiones: Se presentó un caso clínico de carcinoma ameloblástico, entidad patológica de escasa frecuencia. La cirugía constituyó el pilar de tratamiento utilizado. Una vez realizada la resección quirúrgica se reconstruyó el defecto palatino, utilizándose el colgajo del músculo temporal, opción útil para lograr el restablecimiento de las funciones estéticas y funcionales como la deglución y fonación(AU)

ABSTRACT Introduction: Ameloblastic carcinoma is a rare condition emerging as a primary neoplasm or from a preexisting ameloblastoma. Temporalis muscle flap is a therapeutic option frequently used for reconstruction of the defect resulting from surgical exeresis. Objective: Present a clinical case of esthetic and functional restoration by reconstruction with temporalis muscle flap of a maxillary defect caused by exeresis of an ameloblastic carcinoma. The case is presented because of the infrequent occurrence of this condition. Clinical case: A female 49-year-old patient reports "a lump" in her palate of nine months evolution. Physical examination finds an increase in volume in the left infraorbital region. Computed axial tomography was indicated, which revealed the presence of a hyperdense image in the left maxillary sinus with internal calcification causing lysis of the nasal bone and the zygomatic bone, and infiltrating soft tissue. A sample was taken for biopsy, which reported a tumor with a high degree of malignancy corresponding to ameloblastic carcinoma. Chest radiography did not show the presence of lung metastasis. Infra- and mesostructure maxillectomy was performed, the lesion was removed with a surgical safety margin, and the palatine defect was reconstructed with a pediculated temporalis muscle flap. Chemo- and radiotherapy were indicated as adjuvants to the surgical treatment. Postoperative follow-up found good clinical evolution and secondary epithelization of the temporalis muscle in the palatine area with restoration of functions. Conclusions: A clinical case was presented of ameloblastic carcinoma, a condition with a low frequency of occurrence. Surgery was the basic component of the treatment applied. Once surgical resection was performed, the palatine defect was reconstructed by means of a temporalis muscle flap, a useful option to achieve the restoration of esthetic and biological functions, such as swallowing and speech(AU)
Descritores: Retalhos Cirúrgicos/cirurgia
Ameloblastoma/diagnóstico por imagem
Neoplasias Maxilomandibulares/patologia
Reconstrução Mandibular/métodos
-Quimiorradioterapia Adjuvante/métodos
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: CU1.1 - Biblioteca Médica Nacional


  3 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-975602
Autor: Iftikhar, Haissan; Suhail, Anwar; Nathani, Karim Rizwan; Urooba, Amna; Shahzad, Noman; Awan, Sohail; Dhanani, Rahim.
Título: Determination of Factors Associated with Critical Weight Loss in Oral Cavity Carcinoma Patients: A Retrospective Cohort Study
Fonte: Int. arch. otorhinolaryngol. (Impr.);22(4):395-399, Oct.-Dec. 2018. tab, graf.
Idioma: en.
Resumo: Abstract Introduction Critical weight loss is defined as an unintentional weight loss of ≥ 5% at 1 month or ≥ 10% at 6 months from the start of treatment. Critical weight loss leads to deterioration of the immune function and reduced tolerance to treatment (surgery ± radiochemotherapy) as well as increased complication rates. Objective Critical weight loss, defined as a weight loss of ≥ 5% after 1 month or ≥ 10% after 6 months from the start of treatment, is not uncommon in head and neck cancer patients. We aimed to assess the factors associated with critical weight loss during the treatment of oral cavity squamous cell carcinoma patients. Methods A retrospective cohort study was performed at the Aga Khan University Hospital, in Karachi, Pakistan, on 125 patients. Patients receiving adjuvant therapy were considered exposed, and the outcome was critical weight loss. Results The mean age of presentation was 46.9 ± 12.8 years in patients undergoing surgery and adjuvant therapy, with 119 (79.3%) of them being male and 31 (20.7%) female. One hundred and twelve patients (81.3%) developed critical weight loss at 6 months from the start of treatment, and the only significant variable associated with critical weight loss was the stage of the disease (p= 0.03). Conclusion A large proportion of patients with oral cancer developed critical weight loss requiring a need for intervention. The overall stage of the disease is a significant predictor of critical weight loss in patients undergoing treatment.
Descritores: Neoplasias Bucais/complicações
Carcinoma de Células Escamosas/complicações
Perda de Peso
-Esvaziamento Cervical
Neoplasias Bucais/terapia
Carcinoma de Células Escamosas/terapia
Estudos Retrospectivos
Fatores de Risco
Estudos de Coortes
Nutrição Enteral
Desnutrição/etiologia
Dieta
Quimiorradioterapia Adjuvante
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: BR66.1 - Divisão de Biblioteca e Documentação


  4 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-959373
Autor: Sánchez R, César; Maldonado J, Daniela; Jans B, Jaime; Domínguez C, Francisco; Galindo A, Héctor; Camus A, Mauricio; Oddo B, David; Medina A, Lidia; Acevedo C, Francisco.
Título: Aplicación de tres modelos pronósticos en cáncer de mama precoz / Application of three prognostic models in T1N0M0 breast cancer
Fonte: Rev. chil. cir;70(3):212-217, 2018. tab.
Idioma: es.
Resumo: Resumen Objetivo Aplicar tres modelos pronósticos "online" (índice pronóstico de Nothingham (NPI), Adjuvantonline! (AO) y PREDICT utilizados en la práctica oncológica para estratificar a pacientes y definir el uso de terapias adyuvantes en pacientes con cáncer de mama (CM) precoz, para evaluar su correlación y predicción de sobrevida en nuestra población. Métodos Obtuvimos datos clínicos de pacientes con CM invasor T1N0M0, tratados en el Centro de Cáncer de la Pontificia Universidad Católica de Chile, Santiago, Chile, desde enero de 1997 hasta diciembre de 2003. Resultados Analizamos datos de 125 pacientes. Edad mediana fue 55 años (35-80). La mayoría de los tumores fueron carcinomas ductales infiltrantes (72,8%), receptor de estrógeno (RE) positivos (88,8%), 80% recibieron terapia endocrina (TE). El beneficio estimado de la TE y la quimioterapia (QT) en la sobrevida global (SG), determinadas según AO y PREDICT, no fueron significativamente diferentes (1,3% y 1% para QT, p = 0,13; 0,9% y 1% para TE, p = 0,8; respectivamente). El modelo NPI estimó una mediana de SG superior (96%) a la calculada por AO (90,9%) y PREDICT (92,5%). La mortalidad específica por CM fue de 3%, similar a lo observado (3,2%). La mediana de SG estimada por todos los modelos en el grupo de pacientes fallecidos no fue estadísticamente diferente al grupo de sobrevivientes (p = 0,85). Conclusión Los modelos pronósticos predicen apropiadamente la SG en pacientes con CM precoz; sin embargo, en esta serie, no discriminaron pacientes de mal pronóstico.

Objective Apply three prognostic models "online" (Nothingham index (NPI), Adjuvantonline! (AO) and PREDICT used in routine oncology practice in order to stratify patients and define the use of adjuvant therapies in patients with stage I breast cancer (BC) to evaluate its correlation and overall survival (OS) in our population. Methods We obtained patients' medical records data with invasive BC T1N0M0, treated at the Cancer Center of the Pontificia Universidad Católica de Chile, Santiago, Chile, from January 1997 to December 2003. Results We analyzed data from 125 patients. Median age was 55 years (35 80). Most tumors were infiltrating ductal carcinoma (72.8%), estrogen receptor positive (88.8%), 80% received endocrine therapy (ET). The estimated ET and chemotherapy benefit was not significantly different according to the AO and PREDICT models (1.3% and 1% for CT, p = 0.13, 0.9% and 1% for ET p = 0.8, respectively). The estimated median OS on NPI (96%) was higher than calculated by AO (90.9%) and PREDICT (92.5%). Interestingly disease specific mortality estimated was 3%, similar to that observed (3.2%). While the estimated median OS by all models in the group of deceased patients was lower than in surviving, this difference did not reach statistical significance (p = 0.85). Conclusion The prognostic models applied effectively predict OS in Chilean patients with T1N0M0 BC, but in this series, they do not sufficiently discriminate patients with poor prognosis. The addition of co -morbidities to AO does not alter the results.
Descritores: Neoplasias da Mama/diagnóstico
-Prognóstico
Neoplasias da Mama/mortalidade
Neoplasias da Mama/tratamento farmacológico
Taxa de Sobrevida
Estudos Retrospectivos
Seguimentos
Quimiorradioterapia Adjuvante
Limites: Humanos
Feminino
Adulto
Pessoa de Meia-Idade
Idoso
Idoso de 80 Anos ou mais
Tipo de Publ: Estudo Clínico
Responsável: CL61.1 - Biblioteca Central Campus Sur


  5 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1000139
Autor: Rueda Mesías, Miguel; Peralta, Patricio; Mesías, Carolina.
Título: Cirugía Laparoscópica en el Cáncer de Colon, en el Hospital Oncológico Solca Quito / Laparoscopic Surgery in Colon Cancer, at the Solca-Quito Oncological Hospital
Fonte: Oncol. (Guayaquil) = Oncol. (Guayaquil);28(2):103-111, Ago. 30, 2018.
Idioma: es.
Resumo: Introducción: La cirugía para el cáncer de colorrectal consiste en la resección en bloque del tumor y de ≥12 ganglios linfáticos regionales, debe incluir la ligadura alta del vaso principal del segmento. Este conjunto de técnicas pueden ser realizadas por vía laparoscópica y el objetivo del presente estudio es presentar los resultados de un centro único con el abordaje quirúrgico laparoscópico en un grupo de pacientes diagnosticados con cáncer de colorrectal. Métodos: En el departamento de Cirugía Oncológica del Hospital "Solón Espinosa Ayala" de Quito, durante el período Enero del 2009 a Septiembre 2012 se realizó un estudio descriptivo, retrospectivo. Se analizaron todos los casos de pacientes derivados del área con diagnóstico inicial de tumor de colorectal, a los cuales previo a realizarles marcadores tumorales, Tomografía de Tórax-abdomen, y a quienes se les realizó como método diagnóstico colonoscópico. Se excluyeron pacientes con neoplasias de origen secundario, con historias clínicas incompletas que imposibilitaron el análisis. Se estudiaron las variables sexo, edad, localización del tumor, diagnostico histopatológico y morbilidad perioperatoria. El análisis estadístico realizado fue descriptivo. Resultados: Se evaluaron 25 pacientes con diagnóstico tumor de mediastino, con una edad media de 61 años. Fueron 15 mujeres (60 %). El estudio histopatológico post-cirugía fue 10 casos (40 %) con adenocarcinoma moderadamente diferenciado, 7 casos (28 %) con adenocarcinoma bien diferenciado. La resección de ≥12 ganglios linfáticos regionales se realizó en 15 casos (75 %). En 13 casos (52 %) recibieron Adyuvancia. 1 caso requirió conversión a cirugía abierta. Morbilidad se presentó en 2 casos (8 %) con fístula y 1 caso (4 %) neumonía. Conclusión: El adenocarcinoma fue el tumor maligno más frecuente en esta serie. El manejo quirúrgico laparoscópico de tumores colorectales tuvo una baja tasa de complicaciones y un abordaje quirúrgico en el 75 % de los casos con resección de más de 12 ganglios peritumorales.

Introduction: Surgery for colorectal cancer consists of resection in the tumor block and ≥ 12 regional lymph nodes, it must include the ligation of the main vessel of the segment. This set of techniques can be laparoscopically performed and the objective of this study is to present the results of a single center with the surgical laparoscopic surgical approach in a group of patients diagnosed with colorectal cancer. Methods: In the Department of Oncological Surgery of the Hospital "Solón Espinosa Ayala" of Quito, a descriptive, retrospective study was carried out during the period from January 2009 to September 2012. All cases of patients with the initial diagnosis of colorectal tumor, previous examinations, tumor markers, chest-abdomen tomography, and those that have been developed as a colonoscopic diagnostic method will be analyzed. We excluded patients with neoplasms of secondary origin, with incomplete clinical histories that make analysis impossible. The variables sex, age, tumor location, histopathological diagnosis and perioperative morbidity will be studied. The statistical analysis performed was descriptive). Results: 25 patients with mediastinal tumor diagnosis were evaluated, with an average age of 61 years. There were 15 women (60 %). The postoperative histopathological study had 10 cases (40 %) with moderately differentiated adenocarcinoma, 7 cases (28 %) with well differentiated adenocarcinoma. Resection of ≥12 regional lymph nodes was performed in 15 cases (75 %). In 13 cases (52 %) they received adjuvant. 1 case required conversion to open surgery. Morbidity occurred in 2 cases (8 %) with fistula and 1 case (4 %) pneumonia. Conclusion: Adenocarcinoma was the most frequent malignant tumor in this series. Laparoscopic surgical management of colored tumors had a low complication rate and a surgical approach in 75 % of the cases with resection of more than 12 peritumoral lymph nodes.
Descritores: Neoplasias Colorretais
Cirurgia Colorretal
Neoplasias do Colo
-Cirurgia Geral
Laparoscopia
Quimiorradioterapia Adjuvante
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Idoso
Tipo de Publ: Estudo Observacional
Responsável: EC104.1 - Biblioteca


  6 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-909906
Autor: Pucella, María Inés; Gadan, Cecilia; Sardi, Mabel; Del Valle Jaen, Ana; Figari, Marcelo; Lastiri, José María; Cayol, Federico.
Título: Cáncer de cavum. Experiencia institucional / Cancer of cavum. Institutional experience
Fonte: Oncol. clín;23(1):22-26, 2018.
Idioma: es.
Resumo: Los carcinomas epidermoides de cabeza y cuello son un grupo poco frecuente de neoplasias, en los Estados Unidos representan aproximadamente el 3% de todos los tumores. El cáncer de cavum se diferencia de otros tumores de cabeza y cuello por su epidemiología, histología, historia natural y respuesta al tratamiento. Presenta una marcada variación geográfica debido a su etiología multifactorial. En las áreas endémicas, la incidencia y la mortalidad han disminuido en los últimos 30 años. Esto probablemente se deba a cambios en el estilo de vida y avances en la radioterapia (RT) y quimioterapia (QT) sistémica (AU)

Epidermoid carcinomas of the head and neck are a rare group of tumors, in the United States they account for 3% of all cancers. Nasopharyngeal carcinoma differs from others head and neck squamous cells carcinomas in epidemiology, natural history, and response to treatment. Nasopharyngeal carcinoma displays a distinct racial and geographic distribution, which is reflective of its multifactorial etiology. The incidence and mortality has declined over the past 30 years in many endemic areas. This finding is probably a result of a combination of lifestyle modification and advances in radiotherapy and effective systemic agents (AU)
Descritores: Infecções por Vírus Epstein-Barr
Neoplasias Nasofaríngeas/terapia
-Quimiorradioterapia
Quimiorradioterapia Adjuvante
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Responsável: AR144.1 - CIBCHACO - Centro de Información Biomedica del Chaco


  7 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-844353
Autor: Solé Z, Sebastián; Larsen E, Francisco; Solé P, Claudio.
Título: Nueva estrategia terapéutica en cáncer de recto localmente avanzado / A new therapeutic approach of locally advanced rectal cancer
Fonte: Rev. chil. cir;69(2):181-183, abr. 2017.
Idioma: es.
Resumo: El cáncer de recto es una enfermedad frecuente en la población, siendo un problema de salud importante a nivel nacional, con un probable aumento en la incidencia junto con la transición demográfica y epidemiológica de los últimos años. La cirugía ha sido históricamente el pilar fundamental en el tratamiento de esta patología, pero asociándose a una alta tasa de recurrencia, tanto locorregional como a distancia, como único tratamiento. Es por esto que se ha estudiado el agregar terapias adyuvantes a la cirugía, como lo es la radioterapia y quimioterapia. La evidencia ha demostrado que la adyuvancia con radioterapia más quimioterapia se asocia a mayor sobrevida global y menor recurrencia local y a distancia en comparación con la cirugía exclusiva. En el presente artículo se realiza una revisión de los principales estudios que evidencian la ventaja, tanto en sobrevida global como libre de enfermedad, del uso de la adyuvancia con radioterapia más quimioterapia, mencionando la última evidencia disponible sobre el tratamiento del cáncer de recto localmente avanzado y las perspectivas a futuro.

Rectal cancer is a common disease in general population, being a major health problem in our nation, with a likely increase in incidence associated to demographic and epidemiological transition in recent years. Historically, the surgery has been the mainstay in the treatment of this disease, but surgery alone is associated to a high rate of recurrence, both locoregional and distant. This is why it has been studied adding adjuvant therapies to surgery, as is radiotherapy and chemotherapy. The evidence has shown that adjuvant radiotherapy and chemotherapy is associated with increased overall survival and less local and distant recurrence compared to surgery alone. This article is a review of major studies that demonstrate the advantage of using adjuvant radiotherapy and chemotherapy in both overall and disease-free survival, mentioning the last evidence available in treatment of locally advanced rectal cancer.
Descritores: Quimiorradioterapia Adjuvante
Neoplasias Retais/tratamento farmacológico
Neoplasias Retais/radioterapia
Limites: Humanos
Tipo de Publ: Revisão
Responsável: CL1.1 - Biblioteca Central


  8 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-721993
Autor: Rojas, Katerin; Jaime, Ponce; Calderón, Gabriela; Dyer, Richard; Vigil, Carlos; Castañeda, Carlos.
Título: Heterogeneidad intratumoral en cáncer de mama: reporte de dos casos y revisión de la literatura / Intratumoral heterogeneity in breast cancer: case report and literature review
Fonte: Carcinos;3(2):25-28, dic. 2013. graf.
Idioma: es.
Resumo: El cáncer de mama (CM) es una enfermedad de gran complejidad. Presenta una gran variabilidad molecular, lo cual se puede observar cuando se comparan los tumores de distintos pacientes, dos regiones del mismo tumor, los ganglios regionales comprometidos versus el tumor primario y la metástasis a distancia versus la lesión primaria. Reportamos el caso de dos pacientes con CM con heterogeneidad en el fenotipo tumoral del tumor primario; el primer caso presentó dos tumores simultáneos de diferentes características dentro de la misma mama y el segundo caso mostró variación en el fenotipo del tumor luego del tratamiento neoadyuvante (TN). Así mismo, realizamos un análisis de la información publicada recientemente.

Breast Cancer (BC) is a complex disease. It shows notable molecular differences when we compare tumors from different patients, two intra-tumor distant regions, metastasis in regional lymph node versus primary lesion, and distant metastasis versus primary lesion. We report two cases of BC with tumor phenotype heterogeneity of the primary tumor. The first case developed two different simultaneous lesions inside the same breast and the second one developed a change in tumor phenotype after neoadjuvant treatment. Furthermore, we performed an evaluation of recently published information.
Descritores: Neoplasias da Mama
Heterogeneidade Genética
Neoplasias da Mama/genética
Quimiorradioterapia Adjuvante
Limites: Feminino
Idoso de 80 Anos ou mais
Responsável: PE1.1 - Oficina Universitária de Biblioteca


  9 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-721992
Autor: Morante, Zaida; Mas, Luis; Neciosup, Silvia.
Título: Quimioterapia en pacientes con cáncer de vejiga avanzado o metast sico: experiencia en el Instituto Nacional de Enfermedades Neoplásicas / Chemotherapy in patients with metastatic or advanced bladder cancer: Experience at the Instituto Nacional de Enfermedades Neopl sicas
Fonte: Carcinos;3(2):19-24, dic. 2013. graf, tab.
Idioma: es.
Resumo: En nuestro país hay 600 casos nuevos de c ncer de vejiga por año, de los cuales la mitad fallece; la inclusión de quimioterapia adyuvante ha mejorado la supervivencia. El objetivo de este estudio fue describir el resultado del tratamiento del cáncer de vejiga en una cohorte de pacientes tratados con quimioterapia en el INEN. Participaron 630 pacientes diagnosticados con cáncer de vejiga entre los años 2005 a 2010, de los cuales 30 recibieron quimioterapia adyuvante. La mediana de edad fue 59,2 años y el 83,3% fue > 50 años. El 56,7% fueron varones y 37,3% mujeres. El 63,3% presentó cáncer de células transicionales de alto grado/moderadamente diferenciado, el 10% carcinoma de células transicionales de bajo grado y el 13,3% tuvo micrometástasis. El 100% recibió primera línea de quimioterapia, la más frecuente fue sales de platino más gemcitabina (50%). El 33,3% recibió radioterapia. El sitio de metástasis más frecuente fue ganglionar (46,7%) seguido de ósea (23,3%). Las medianas de seguimiento y de sobrevida global fueron 28 y 14,7 meses respectivamente (SG a 5 años 12,5%). Los factores asociados con la sobrevida global fueron el compromiso ganglionar (con compromiso, SG de 28,2 meses vs sin compromiso, SG de 5,5 meses; tasa a 5 años de 23,2% vs 16,7%; P=0,031); y el tipo de quimioterapia, mediana de SG de 29,4 meses para gemcitabina-cisplatino (tasa a 5 años de 17,5%). En conclusión, los tiempos de sobrevida observados en el estudio fueron semejantes a los reportados, el compromiso ganglionar fue un factor prognóstico para la sobrevida global y el mejor tratamiento fue la combinación de gemcitabina más cisplatino.

There are 600 new cases of bladder cancer per year in our country, of which half dies, however the inclusion of adjuvant chemotherapy has improved survival. The aim of this study was to describe the results of bladder cancer treatment in a cohort of patients treated with chemotherapy at the INEN. Six hundred and thirty patients diagnosed with bladder cancer between 2005 to 2010 were included, of which 30 received adjuvant chemotherapy. The median age was 59.2 years and 83.3% were > 50 years. More than the fifty six percent (56.7%)of patients were male and 37.3% female; 63.3% had cancer of transitional cell high grade/ moderately differentiated, 10% had low grade transitional cell carcinoma and 13.3% had micrometastases. All patients received first-line chemotherapy, the most common was platinum salts plus gemcitabine (50%). The 33.3% of patients received radiotherapy. The most common site of metastasis was nodal (46.7%) followed by bone (23.3%). Median follow-up and overall survival were 28 and 14.7 months, respectively (5-year OS 12.5%). Factors associated with overall survival were nodal involvement (involved, OS 28.2 months vs not involved, OS 5.5 months; 5-year rate 23.2% vs 16.7%, P = 0.031) and the type of chemotherapy, median OS of 29.4 months for gemcitabine - cisplatin (5-year rate 17.5%). In conclusion, the survival times observed in this study were similar to previously reported, nodal involvement was predictive for overall survival and the best treatment factor was the combination of gemcitabine plus cisplatin.
Descritores: Neoplasias da Bexiga Urinária/tratamento farmacológico
Quimiorradioterapia Adjuvante
Sobrevida
-Estudos de Coortes
Epidemiologia Descritiva
Estudos Retrospectivos
Limites: Feminino
Pessoa de Meia-Idade
Idoso de 80 Anos ou mais
Responsável: PE1.1 - Oficina Universitária de Biblioteca


  10 / 18 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-713003
Autor: Andreoli, Silmara Cristiane da Silveira; Gasparini, Nina Jardim; Carvalho, Gisele Pereira de; Garicochea, Bernardo; Pogue, Robert Edward; Andrade, Rosângela Vieira de.
Título: Use of microRNAs in directing therapy and evaluating treatment response in colorectal cancer / Utilização dos microRNAs no direcionamento da terapia e na avaliação da resposta ao tratamento do câncer colorretal
Fonte: Einstein (Säo Paulo);12(2):256-258, Apr-Jun/2014. graf.
Idioma: en.
Resumo: Colorectal cancer is the third most common cancer worldwide. Survival and prognosis depend on tumor stage upon diagnosis, and in more than 50% of cases, the tumor has already invaded adjacent tissues or metastasis has occurred. Aiming to improve diagnosis, clinical prognosis and treatment of patients with colorectal cancer, several studies have investigated microRNAs as molecular markers of the disease due to their potential regulatory functions on tumor suppressor genes and oncogenes. This review aimed to summarize the main topics related to the use of microRNAs in diagnosis, clinical prognosis and evaluating treatment response in colorectal cancer.

O câncer colorretal é o terceiro tipo de câncer mais comum em todo o mundo. A sobrevivência e o prognóstico dependem do estágio do tumor no diagnóstico, momento em que, em mais de 50% dos casos, o tumor já invadiu tecidos adjacentes ou ocorreu metástase. Objetivando-se melhorar o diagnóstico, o prognóstico clínico e o tratamento de pacientes com câncer colorretal, vários estudos investigaram microRNAs como marcadores moleculares da doença, devido à sua função reguladora potencial sobre genes supressores de tumor e oncogenes. Esta revisão procura resumir os principais tópicos relacionados ao uso de microRNAs no diagnóstico, na determinação do prognóstico clínico e na avaliação de resposta ao tratamento do câncer colorretal.
Descritores: Neoplasias Colorretais/genética
MicroRNAs/metabolismo
-Antineoplásicos/uso terapêutico
Quimiorradioterapia Adjuvante
Neoplasias Colorretais/tratamento farmacológico
Neoplasias Colorretais/patologia
Desoxicitidina/análogos & derivados
Desoxicitidina/uso terapêutico
Fluoruracila/análogos & derivados
Fluoruracila/uso terapêutico
Regulação Neoplásica da Expressão Gênica
Marcadores Genéticos
Estadiamento de Neoplasias
Invasividade Neoplásica/genética
Compostos Organoplatínicos/uso terapêutico
Prognóstico
Estilbenos/uso terapêutico
Limites: Humanos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME



página 1 de 2 ir para página        
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde